An interventional study of MANOEUVRE therapy in Psychosis, SCHIZOPHRENIA 1 (Disorder) and Schizophrenia and Related Disorders, sponsored by King's College London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by King's College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Psychotic Disorders by King's College London — 12 open to participants now, 12 under way, none of them phase 3. Psychotic Disorders · King's College London.
Among the 26 studies in Psychotic Disorders by King's College London, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2027, is one of 15 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 23rd registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →12 of the 26 studies in Psychotic Disorders by King's College London are open now, in 3 countries. Recruiting first, the newest first:
King's College London · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
King's College London · Sites in United Kingdom
Ages 18–65
King's College London · Sites in United Kingdom
Ages 18–40 · Healthy volunteers
King's College London · Sites in United Kingdom
Ages 12–35 · Healthy volunteers
King's College London · Sites in Ethiopia, India
Ages 18+
By country, each count listing its studies:
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1
First in 2013; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 15 is below the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 24 across the 18 interventional studies, 193 across the 8 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.
2 of the studies in Psychotic Disorders by King's College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06957808King's College LondonInvestigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia | 2027-01-20 |
| NCT07939347King's College LondonAVATAR Therapy for Distressing Voices in India and Ethiopia | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Psychotic Disorders by King's College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Supporting people with psychosis to manage their emotions using virtual reality
Many people who have experienced psychosis feel overwhelmed by their emotions. Emotions get in the way of doing what matters to them. They want support to manage emotions differently. There is evidence that people with psychosis find talking therapies that teach skills for managing emotions helpful. People said it helped them to understand and manage their emotions. However, they also wanted more help to apply skills they learned to their lives.
It is hard to help people to use therapy skills in real-life situations. Therapists cannot be present when the skills are needed. One solution is to use virtual reality (VR) to bridge the gap between the clinic and real-life. VR involves using a headset to see and hear a very life-like computer-generated simulation of everyday life situations. People with psychosis find VR therapies engaging and helpful. It can feel safer to try things out in VR.
Guided by the feedback of people with psychosis, this research will evaluate a novel therapy to help people with psychosis manage their emotions. Face-to- face therapy will be combined with VR so that people can practice emotion regulation skills safely with "live" coaching from a therapist. This should support people to use these skills when they need them.
Fifteen people with psychosis will be offered the therapy. Everyone will be asked what they think of it and complete questionnaires before and after therapy to see what impact it had on their lives.
A lived experience advisory group will support all aspects of the research process.
Background Many people with psychosis report difficulties understanding and managing their emotions (emotion regulation difficulties), yet evidence-based interventions are lacking. Brief interventions that teach emotion regulation skills show promise but service users report wanting additional support to apply what they have learned in therapy to their lives.
Aim: To test the initial feasibility and acceptability of a VR-assisted therapy (called MANaging emOtions in Everyday life Using Virtual REality; MANOEUVRE) for emotion regulation difficulties in psychosis
Methods A mixed methods case series will be undertaken. The study will recruit people with psychosis from NHS community care teams (in England). Assessments will be at baseline, post therapy and 3-month follow up. Feasibility and acceptability of a future trial will be assessed based on uptake/ recruitment, data completeness and qualitative feedback. Feasibility and assessment of the therapy will be assessed based on adherence, acceptability (sessional feedback ratings, qualitative interview feedback, side effect and satisfaction ratings), safety (adverse effects), implementation resources and fidelity.
Participants will complete measures of emotion regulation difficulties, adaptive emotion regulation skill use, psychological distress, personal recovery goal achievement and quality of life. To assess feasibility, individual-level changes will be calculated using the reliable change index to assess whether changes are more likely to reflect measurement error or actual clinical change. Group-level changes will be assessed using means and standard deviations and effect sizes (Cohen's d) with confidence intervals . A post therapy semi-structured interview will explore participants' experience of receiving MANOEUVRE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: MANOEUVRE therapy
Virtual reality assisted psychological therapy for emotion regulation difficulties
Difficulties in Emotion Regulation Scale 16 item version (DERS-16)
Self reported emotion regulation difficulties
Time frame: Pre therapy, immediately after therapy, 3 month follow up
DBT Ways of Coping Checklist - DBT Skills Subscale
Adaptive use of emotion regulation skills
Time frame: Pre therapy, immediately after therapy, follow up
Clinical Outcomes in Routine Evaluation-10 item version (CORE-10)
Psychological distress
Time frame: Pre therapy, immediately after therapy, 3 month follow up
Goal Attainment Scaling (GAS)
Personal recovery goal achievement
Time frame: Pre therapy, immediately after therapy, 3 month follow up
Recovering Quality of Life (ReQoL-10)
Quality of life
Time frame: Pre therapy, immediately after therapy, 3 month follow up
Plan to share: Yes — Individual participant data that underlie the results after deidentification
Time frame: After publication
Access criteria: The final anonymised study dataset will be available to other researchers at the end of the programme provided that does not compromise confidentiality.
Start is estimated for Sep 2027; primary completion for May 2028, 8 months later.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 8 months is below that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.